Aravive Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Aravive Stock Forecast and Price Target
If the average price target of $0.02 set by distinguished experts for Aravive over the past few weeks is reached this year, there would be a potential downside of approximately -50% from the last closing price in January, 2024. This potential increase is based on a high estimate of $0.02 and a low estimate of $0.02. If you're thinking of investing in ARAV stock, it might be good to look at its rivals too.
-50.00% Downside
Aravive Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Aravive's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $0.04 – an increase of 100.00%. Over the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$160.81 | Buy/Sell | $178.42 | 15.04% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$278.39 | Buy/Sell | $303.65 | 14.77% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.33 | Buy/Sell | $87.82 | 22.46% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$213.51 | Buy/Sell | $299.62 | 35.12% |
Aravive Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Aravive's Revenue has grown from $5.69M to $9.14M – a 60.63% increase. In the next year, 3 analysts estimate that Aravive's Revenue will decrease by 74.51%, reaching $2.33M. According to professional forecasts, in 2030, Aravive's Revenue will decrease by 22.32%, reaching $7.10M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$83.80 | Buy/Sell | $111.56 | 31.26% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$53.09 | Buy/Sell | $77.05 | 47.86% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$75.76 | Buy/Sell | $34.00 | 51.80% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$107.00 | Buy/Sell | $85.71 | 2.80% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$12.88 | Buy/Sell | $20.42 | 97.98% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
Aravive EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Aravive's EBITDA has grown, rising from $-23.27M to $-69.95M – a growth of 200.60%. 1 analysts predict Aravive's EBITDA will decrease by 20.80% in the next year, reaching $-55.40M. For the next seven years, the forecast is for EBITDA to grow by 33.42%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.43 | Buy/Sell | $17.90 | 91.75% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.13 | Buy/Sell | $52.00 | 127.93% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.08 | Buy/Sell | $33.78 | 75.64% |
Aravive EBIT Forecast for 2023 - 2025 - 2030
Aravive's EBIT has grown In the last two years, rising from $-25.00M to $-70.84M – a growth of 183.36%. For the following year, the 3 analysts predict that Aravive's EBIT will drop by 67.81%, reaching $-22.80M. In 2030, the professionals' prediction is that ARAV's EBIT will decrease by 99.58%, reaching $-300.00k.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$40.86 | Buy/Sell | $63.29 | 88.45% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.88 | Buy/Sell | $42.58 | 14.87% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.58 | Buy/Sell | $40.00 | 28.69% |
Aravive EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Aravive's EPS has grown from $-1.57 to $0.00 – a 100.00% increase. Next year, analysts are expecting EPS to reach $-0.29 – an increase of 100.00%. Over the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.79 | Buy/Sell | $9.94 | 98.82% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.74 | Buy/Sell | $6.00 | 18.69% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.72 | Buy/Sell | $25.00 | 109.04% |
.jpg)